| 1. |
GLOBAL MHEALTH MARKET–REPORT OVERVIEW |
20 |
| 1.1. |
SCOPE OF THE REPORT |
21 |
| 1.2. |
MARKET SEGMENT ANALYSIS |
22 |
| 1.3. |
REGULATORY SCENARIO BY REGION/COUNTRY |
25 |
| 1.4. |
MARKET INVESTMENT SCENARIO STRATEGIC |
25 |
| 1.5. |
MARKET ANALYSIS BY OFFERING (USD MILLION) |
26 |
| 1.5.1 |
GLOBAL MHEALTH MARKET SHARE BY OFFERING (2024-2040) |
26 |
| 1.5.2 |
MHEALTH APPLICATIONS AND SOFTWARE |
26 |
| 1.5.2.1 |
Standalone mHealth Applications |
26 |
| 1.5.2.2 |
Connected-Device Companion Applications |
26 |
| 1.5.2.3 |
Clinical Mobile Software |
26 |
| 1.5.2.4 |
Enterprise mHealth Platforms |
26 |
| 1.5.2.5 |
mHealth Data Integration and Analytics Software |
26 |
| 1.5.3 |
CONNECTED MHEALTH DEVICES |
26 |
| 1.5.3.1 |
Wearable mHealth Devices |
26 |
| 1.5.3.2 |
Handheld and Portable Monitoring Devices |
26 |
| 1.5.3.3 |
Smartphone-Connected Diagnostic Accessories |
26 |
| 1.5.3.4 |
Connected Home Health Monitoring Devices |
26 |
| 1.5.3.5 |
Connected Medication Delivery and Adherence Devices |
26 |
| 1.5.3.6 |
Connected Implantable Monitoring and Therapeutic Devices |
26 |
| 1.5.4 |
MHEALTH SERVICES |
26 |
| 1.5.4.1 |
Remote Patient Monitoring Services |
26 |
| 1.5.4.2 |
Mobile Teleconsultation Services |
26 |
| 1.5.4.3 |
Mobile Diagnostic and Screening Services |
26 |
| 1.5.4.4 |
Mobile Treatment and Therapy Support Services |
26 |
| 1.5.4.5 |
Mobile Rehabilitation Services |
26 |
| 1.5.4.6 |
Mobile Health Information and Education Services |
26 |
| 1.5.4.7 |
Mobile Care Coordination Services |
26 |
| 1.5.4.8 |
Mobile Emergency Response Services |
26 |
| 1.6. |
GLOBAL MHEALTH MARKET SHARE BY OFFERING IN 2024 & 2040 |
27 |
| 1.7. |
MARKET ANALYSIS BY MHEALTH APPLICATION TYPE (USD MILLION) |
28 |
| 1.7.1 |
GLOBAL MHEALTH MARKET SHARE BY MHEALTH APPLICATION TYPE (2024-2040) |
28 |
| 1.7.2 |
MEDICAL AND CLINICAL APPLICATIONS |
29 |
| 1.7.2.1 |
Chronic Disease Management Applications |
29 |
| 1.7.2.1.1 |
Diabetes Management Applications |
29 |
| 1.7.2.1.2 |
Cardiovascular Disease Management Applications |
29 |
| 1.7.2.1.3 |
Respiratory Disease Management Applications |
29 |
| 1.7.2.1.4 |
Neurological Disease Management Applications |
29 |
| 1.7.2.1.5 |
Cancer Management Applications |
29 |
| 1.7.2.1.6 |
Renal Disease Management Applications |
29 |
| 1.7.2.1.7 |
Musculoskeletal and Chronic Pain Management Applications |
29 |
| 1.7.2.1.8 |
Other Chronic Disease Management Applications |
29 |
| 1.7.2.2 |
Medication Management and Adherence Applications |
29 |
| 1.7.2.3 |
Symptom Assessment and Patient-Triage Applications |
29 |
| 1.7.2.4 |
Diagnostic and Screening Applications |
29 |
| 1.7.2.5 |
Clinical Decision-Support Applications |
29 |
| 1.7.2.6 |
Medical Reference and Professional Education Applications |
29 |
| 1.7.2.7 |
Electronic Prescription Applications |
29 |
| 1.7.2.8 |
Patient Portal and Personal Health Record Applications |
29 |
| 1.7.2.9 |
Mental and Behavioral Health Applications |
29 |
| 1.7.2.10 |
Women’s, Reproductive and Maternal Health Applications |
29 |
| 1.7.2.11 |
Rehabilitation and Physiotherapy Applications |
29 |
| 1.7.2.12 |
Digital Therapeutics Applications |
29 |
| 1.7.2.13 |
Emergency Care and First-Aid Applications |
29 |
| 1.7.2.14 |
Clinical Communication and Care-Team Collaboration Applications |
29 |
| 1.7.3 |
WELLNESS AND PREVENTIVE HEALTH APPLICATIONS |
29 |
| 1.7.3.1 |
Fitness and Physical Activity Applications |
29 |
| 1.7.3.2 |
Nutrition and Diet Management Applications |
29 |
| 1.7.3.3 |
Weight Management Applications |
29 |
| 1.7.3.4 |
Sleep and Recovery Applications |
29 |
| 1.7.3.5 |
Stress Management and Mindfulness Applications |
29 |
| 1.7.3.6 |
Smoking and Substance-Cessation Applications |
29 |
| 1.7.3.7 |
Preventive Health and Lifestyle-Coaching Applications |
29 |
| 1.7.3.8 |
Healthy Ageing Applications |
29 |
| 1.8. |
GLOBAL MHEALTH MARKET SHARE BY MHEALTH APPLICATION TYPE IN 2024 & 2040 |
30 |
| 1.9. |
MARKET ANALYSIS BY CONNECTED DEVICE FORM FACTOR (USD MILLION) |
31 |
| 1.9.1 |
GLOBAL MHEALTH MARKET SHARE BY CONNECTED DEVICE FORM FACTOR (2024-2040) |
31 |
| 1.9.2 |
WEARABLE DEVICES |
32 |
| 1.9.2.1 |
Smartwatches and Fitness Bands |
32 |
| 1.9.2.2 |
Wearable Medical Patches |
32 |
| 1.9.2.3 |
Smart Clothing and Electronic Textiles |
32 |
| 1.9.2.4 |
Head-Worn and Ear-Worn Devices |
32 |
| 1.9.2.5 |
Wearable Rings |
32 |
| 1.9.2.6 |
Other Wearable Devices |
32 |
| 1.9.3 |
HANDHELD AND PORTABLE DEVICES |
32 |
| 1.9.3.1 |
Handheld Vital-Sign Monitors |
32 |
| 1.9.3.2 |
Portable Cardiac Monitoring Devices |
32 |
| 1.9.3.3 |
Portable Respiratory Monitoring Devices |
32 |
| 1.9.3.4 |
Portable Metabolic Monitoring Devices |
32 |
| 1.9.3.5 |
Other Handheld and Portable Devices |
32 |
| 1.9.4 |
SMARTPHONE- AND TABLET-CONNECTED ACCESSORIES |
32 |
| 1.9.4.1 |
Smartphone-Connected ECG Devices |
32 |
| 1.9.4.2 |
Smartphone-Connected Blood Pressure Monitors |
32 |
| 1.9.4.3 |
Smartphone-Connected Glucose Monitoring Devices |
32 |
| 1.9.4.4 |
Smartphone-Connected Pulse Oximeters |
32 |
| 1.9.4.5 |
Smartphone-Connected Otoscopes |
32 |
| 1.9.4.6 |
Smartphone-Connected Dermatoscopes |
32 |
| 1.9.4.7 |
Smartphone-Connected Ultrasound Devices |
32 |
| 1.9.4.8 |
Smartphone-Connected Laboratory and Diagnostic Readers |
32 |
| 1.9.4.9 |
Other Smartphone-Connected Accessories |
32 |
| 1.9.5 |
CONNECTED HOME HEALTH DEVICES |
32 |
| 1.9.5.1 |
Connected Blood Pressure Monitors |
32 |
| 1.9.5.2 |
Connected Blood Glucose Monitors |
32 |
| 1.9.5.3 |
Connected Pulse Oximeters |
32 |
| 1.9.5.4 |
Connected Weighing Scales |
32 |
| 1.9.5.5 |
Connected Thermometers |
32 |
| 1.9.5.6 |
Connected Respiratory Devices |
32 |
| 1.9.5.7 |
Connected Multi-Parameter Monitors |
32 |
| 1.9.5.8 |
Other Connected Home Health Devices |
32 |
| 1.9.6 |
CONNECTED MEDICATION MANAGEMENT DEVICES |
32 |
| 1.9.6.1 |
Connected Inhalers |
32 |
| 1.9.6.2 |
Connected Insulin Pens |
32 |
| 1.9.6.3 |
Connected Insulin Pumps |
32 |
| 1.9.6.4 |
Connected Injection Devices |
32 |
| 1.9.6.5 |
Smart Pill Dispensers |
32 |
| 1.9.6.6 |
Smart Medication Packaging |
32 |
| 1.9.6.7 |
Other Connected Medication Devices |
33 |
| 1.9.7 |
CONNECTED IMPLANTABLE DEVICES |
33 |
| 1.9.7.1 |
Connected Cardiac Implantable Devices |
33 |
| 1.9.7.2 |
Connected Implantable Glucose Sensors |
33 |
| 1.9.7.3 |
Connected Neurostimulation Devices |
33 |
| 1.9.7.4 |
Other Connected Implantable Devices |
33 |
| 1.10. |
GLOBAL MHEALTH MARKET SHARE BY CONNECTED DEVICE FORM FACTOR IN 2024 & 2040 |
34 |
| 1.11. |
MARKET ANALYSIS BY MONITORING AND MEASUREMENT FUNCTION (USD MILLION) |
35 |
| 1.11.1 |
GLOBAL MHEALTH MARKET SHARE BY MONITORING AND MEASUREMENT FUNCTION (2024-2040) |
35 |
| 1.11.2 |
SINGLE-PARAMETER MONITORING |
35 |
| 1.11.2.1 |
Cardiac Rhythm and ECG Monitoring |
35 |
| 1.11.2.2 |
Heart-Rate Monitoring |
35 |
| 1.11.2.3 |
Blood Pressure Monitoring |
35 |
| 1.11.2.4 |
Blood Glucose Monitoring |
35 |
| 1.11.2.5 |
Blood-Oxygen Saturation Monitoring |
35 |
| 1.11.2.6 |
Respiratory Rate and Lung-Function Monitoring |
35 |
| 1.11.2.7 |
Body-Temperature Monitoring |
35 |
| 1.11.2.8 |
Sleep Monitoring |
35 |
| 1.11.2.9 |
Neurological and Brain-Activity Monitoring |
35 |
| 1.11.2.10 |
Physical Activity and Energy-Expenditure Monitoring |
35 |
| 1.11.2.11 |
Weight and Body-Composition Monitoring |
35 |
| 1.11.2.12 |
Maternal and Fetal Monitoring |
35 |
| 1.11.2.13 |
Medication-Usage Monitoring |
35 |
| 1.11.2.14 |
Other Single-Parameter Monitoring |
35 |
| 1.11.3 |
MULTI-PARAMETER MONITORING |
35 |
| 1.11.3.1 |
Consumer Multi-Parameter Monitoring |
35 |
| 1.11.3.2 |
Clinical Multi-Parameter Monitoring |
35 |
| 1.12. |
GLOBAL MHEALTH MARKET SHARE BY MONITORING AND MEASUREMENT FUNCTION IN 2024 & 2040 |
36 |
| 1.13. |
MARKET ANALYSIS BY PRIMARY CLINICAL USE CASE (USD MILLION) |
37 |
| 1.13.1 |
GLOBAL MHEALTH MARKET SHARE BY PRIMARY CLINICAL USE CASE (2024-2040) |
37 |
| 1.13.2 |
HEALTH PROMOTION AND DISEASE PREVENTION |
38 |
| 1.13.3 |
RISK ASSESSMENT AND EARLY SCREENING |
38 |
| 1.13.4 |
DIAGNOSIS AND CLINICAL DECISION SUPPORT |
38 |
| 1.13.5 |
CONTINUOUS AND INTERMITTENT PATIENT MONITORING |
38 |
| 1.13.6 |
TREATMENT AND THERAPEUTIC INTERVENTION |
38 |
| 1.13.7 |
MEDICATION MANAGEMENT AND ADHERENCE |
38 |
| 1.13.8 |
REHABILITATION AND RECOVERY MANAGEMENT |
38 |
| 1.13.9 |
POST-TREATMENT FOLLOW-UP |
38 |
| 1.13.10 |
PATIENT EDUCATION AND SELF-MANAGEMENT |
38 |
| 1.13.11 |
CLINICAL COMMUNICATION AND CARE COORDINATION |
38 |
| 1.13.12 |
EMERGENCY DETECTION AND RESPONSE |
38 |
| 1.13.13 |
PUBLIC-HEALTH SURVEILLANCE AND POPULATION MANAGEMENT |
38 |
| 1.14. |
GLOBAL MHEALTH MARKET SHARE BY PRIMARY CLINICAL USE CASE IN 2024 & 2040 |
39 |
| 1.15. |
MARKET ANALYSIS BY DISEASE AND THERAPEUTIC AREA (USD MILLION) |
40 |
| 1.15.1 |
GLOBAL MHEALTH MARKET SHARE BY DISEASE AND THERAPEUTIC AREA (2024-2040) |
40 |
| 1.15.2 |
CARDIOVASCULAR DISEASES |
41 |
| 1.15.2.1 |
Hypertension |
41 |
| 1.15.2.2 |
Arrhythmia |
41 |
| 1.15.2.3 |
Heart Failure |
41 |
| 1.15.2.4 |
Coronary Artery Disease |
41 |
| 1.15.2.5 |
Other Cardiovascular Diseases |
41 |
| 1.15.3 |
DIABETES AND METABOLIC DISORDERS |
41 |
| 1.15.3.1 |
Type 1 Diabetes |
41 |
| 1.15.3.2 |
Type 2 Diabetes |
41 |
| 1.15.3.3 |
Obesity and Weight-Related Disorders |
41 |
| 1.15.3.4 |
Other Metabolic Disorders |
41 |
| 1.15.4 |
RESPIRATORY DISEASES |
41 |
| 1.15.4.1 |
Asthma |
41 |
| 1.15.4.2 |
Chronic Obstructive Pulmonary Disease |
41 |
| 1.15.4.3 |
Sleep Apnea |
41 |
| 1.15.4.4 |
Other Respiratory Diseases |
41 |
| 1.15.5 |
MENTAL AND BEHAVIORAL HEALTH DISORDERS |
41 |
| 1.15.5.1 |
Anxiety Disorders |
41 |
| 1.15.5.2 |
Depression |
41 |
| 1.15.5.3 |
Stress-Related Disorders |
41 |
| 1.15.5.4 |
Substance-Use Disorders |
41 |
| 1.15.5.5 |
Other Mental and Behavioral Disorders |
41 |
| 1.15.6 |
NEUROLOGICAL DISORDERS |
41 |
| 1.15.6.1 |
Epilepsy |
41 |
| 1.15.6.2 |
Parkinson’s Disease |
41 |
| 1.15.6.3 |
Alzheimer’s Disease and Dementia |
41 |
| 1.15.6.4 |
Migraine and Headache Disorders |
41 |
| 1.15.6.5 |
Other Neurological Disorders |
41 |
| 1.15.7 |
ONCOLOGY |
41 |
| 1.15.7.1 |
Treatment Monitoring |
41 |
| 1.15.7.2 |
Symptom and Side-Effect Management |
41 |
| 1.15.7.3 |
Survivorship and Follow-Up Care |
41 |
| 1.15.8 |
MUSCULOSKELETAL AND PAIN DISORDERS |
41 |
| 1.15.8.1 |
Chronic Pain |
41 |
| 1.15.8.2 |
Arthritis |
41 |
| 1.15.8.3 |
Orthopedic Rehabilitation |
41 |
| 1.15.8.4 |
Other Musculoskeletal Disorders |
41 |
| 1.15.9 |
WOMEN’S AND REPRODUCTIVE HEALTH |
42 |
| 1.15.9.1 |
Menstrual Health |
42 |
| 1.15.9.2 |
Fertility and Conception |
42 |
| 1.15.9.3 |
Pregnancy and Maternal Health |
42 |
| 1.15.9.4 |
Postpartum Health |
42 |
| 1.15.9.5 |
Menopause Management |
42 |
| 1.15.10 |
RENAL AND UROLOGICAL DISEASES |
42 |
| 1.15.11 |
GASTROINTESTINAL DISEASES |
42 |
| 1.15.12 |
INFECTIOUS DISEASES |
42 |
| 1.15.13 |
DERMATOLOGICAL DISEASES |
42 |
| 1.15.14 |
OPHTHALMIC DISORDERS |
42 |
| 1.15.15 |
RARE DISEASES |
42 |
| 1.15.16 |
OTHER DISEASE AND THERAPEUTIC AREAS |
42 |
| 1.16. |
GLOBAL MHEALTH MARKET SHARE BY DISEASE AND THERAPEUTIC AREA IN 2024 & 2040 |
43 |
| 1.17. |
MARKET ANALYSIS BY PRIMARY USER (USD MILLION) |
44 |
| 1.17.1 |
GLOBAL MHEALTH MARKET SHARE BY PRIMARY USER (2024-2040) |
44 |
| 1.17.2 |
PATIENTS AND CONSUMERS |
45 |
| 1.17.3 |
PHYSICIANS |
45 |
| 1.17.4 |
NURSES |
45 |
| 1.17.5 |
PHARMACISTS |
45 |
| 1.17.6 |
PHYSIOTHERAPISTS AND REHABILITATION PROFESSIONALS |
45 |
| 1.17.7 |
BEHAVIORAL AND MENTAL HEALTH PROFESSIONALS |
45 |
| 1.17.8 |
DIETITIANS AND NUTRITION PROFESSIONALS |
45 |
| 1.17.9 |
CAREGIVERS AND FAMILY MEMBERS |
45 |
| 1.17.10 |
COMMUNITY HEALTH WORKERS |
45 |
| 1.17.11 |
EMERGENCY MEDICAL PERSONNEL |
45 |
| 1.17.12 |
CLINICAL RESEARCHERS |
45 |
| 1.17.13 |
HEALTHCARE ADMINISTRATIVE PERSONNEL |
45 |
| 1.18. |
GLOBAL MHEALTH MARKET SHARE BY PRIMARY USER IN 2024 & 2040 |
46 |
| 1.19. |
MARKET ANALYSIS BY CUSTOMER TYPE (USD MILLION) |
47 |
| 1.19.1 |
GLOBAL MHEALTH MARKET SHARE BY CUSTOMER TYPE (2024-2040) |
47 |
| 1.19.2 |
DIRECT-TO-CONSUMER CUSTOMERS |
47 |
| 1.19.3 |
HEALTHCARE PROVIDERS |
47 |
| 1.19.3.1 |
Hospitals and Health Systems |
47 |
| 1.19.3.2 |
Physician Practices and Clinics |
47 |
| 1.19.3.3 |
Diagnostic Centers |
47 |
| 1.19.3.4 |
Rehabilitation Centers |
47 |
| 1.19.3.5 |
Home Healthcare Providers |
47 |
| 1.19.3.6 |
Long-Term Care Providers |
47 |
| 1.19.4 |
HEALTH INSURANCE COMPANIES AND PAYERS |
47 |
| 1.19.5 |
PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES |
47 |
| 1.19.6 |
MEDICAL DEVICE COMPANIES |
47 |
| 1.19.7 |
EMPLOYERS AND CORPORATE WELLNESS PROVIDERS |
47 |
| 1.19.8 |
GOVERNMENT AND PUBLIC-HEALTH ORGANIZATIONS |
47 |
| 1.19.9 |
RESEARCH INSTITUTES AND ACADEMIC ORGANIZATIONS |
47 |
| 1.19.10 |
NON-GOVERNMENTAL AND HUMANITARIAN ORGANIZATIONS |
47 |
| 1.20. |
GLOBAL MHEALTH MARKET SHARE BY CUSTOMER TYPE IN 2024 & 2040 |
48 |
| 1.21. |
MARKET ANALYSIS BY CARE SETTING (USD MILLION) |
49 |
| 1.21.1 |
GLOBAL MHEALTH MARKET SHARE BY CARE SETTING (2024-2040) |
49 |
| 1.21.2 |
HOME-BASED CARE |
49 |
| 1.21.3 |
HOSPITALS |
49 |
| 1.21.4 |
AMBULATORY CLINICS AND PHYSICIAN OFFICES |
49 |
| 1.21.5 |
DIAGNOSTIC AND IMAGING CENTERS |
49 |
| 1.21.6 |
PHARMACIES AND RETAIL HEALTH SETTINGS |
49 |
| 1.21.7 |
REHABILITATION CENTERS |
49 |
| 1.21.8 |
LONG-TERM CARE AND ASSISTED-LIVING FACILITIES |
49 |
| 1.21.9 |
COMMUNITY AND FIELD-BASED HEALTHCARE |
49 |
| 1.21.10 |
WORKPLACE AND CORPORATE HEALTH SETTINGS |
49 |
| 1.21.11 |
EMERGENCY AND PREHOSPITAL SETTINGS |
49 |
| 1.22. |
GLOBAL MHEALTH MARKET SHARE BY CARE SETTING IN 2024 & 2040 |
50 |
| 1.23. |
MARKET ANALYSIS BY DEPLOYMENT MODEL (USD MILLION) |
51 |
| 1.23.1 |
GLOBAL MHEALTH MARKET SHARE BY DEPLOYMENT MODEL (2024-2040) |
51 |
| 1.23.2 |
CLOUD-BASED MHEALTH SOLUTIONS |
51 |
| 1.23.3 |
ON-DEVICE AND EDGE-BASED MHEALTH SOLUTIONS |
51 |
| 1.23.4 |
ON-PREMISES ENTERPRISE MHEALTH SOLUTIONS |
51 |
| 1.23.5 |
HYBRID MHEALTH SOLUTIONS |
51 |
| 1.24. |
GLOBAL MHEALTH MARKET SHARE BY DEPLOYMENT MODEL IN 2024 & 2040 |
52 |
| 1.25. |
MARKET ANALYSIS BY DELIVERY MODEL (USD MILLION) |
53 |
| 1.25.1 |
GLOBAL MHEALTH MARKET SHARE BY DELIVERY MODEL (2024-2040) |
53 |
| 1.25.2 |
BUSINESS-TO-CONSUMER |
53 |
| 1.25.3 |
BUSINESS-TO-BUSINESS |
53 |
| 1.25.4 |
BUSINESS-TO-BUSINESS-TO-CONSUMER |
53 |
| 1.25.5 |
GOVERNMENT-TO-CITIZEN |
53 |
| 1.26. |
GLOBAL MHEALTH MARKET SHARE BY DELIVERY MODEL IN 2024 & 2040 |
54 |
| 1.27. |
MARKET ANALYSIS BY PRIMARY REVENUE MODEL (USD MILLION) |
55 |
| 1.27.1 |
GLOBAL MHEALTH MARKET SHARE BY PRIMARY REVENUE MODEL (2024-2040) |
55 |
| 1.27.2 |
SUBSCRIPTION-BASED MODEL |
55 |
| 1.27.2.1 |
Monthly Subscription |
55 |
| 1.27.2.2 |
Annual Subscription |
55 |
| 1.27.2.3 |
Enterprise Subscription |
55 |
| 1.27.3 |
ONE-TIME APPLICATION OR SOFTWARE LICENSING |
55 |
| 1.27.4 |
PAY-PER-CONSULTATION OR PAY-PER-USE |
55 |
| 1.27.5 |
CONNECTED-DEVICE SALES AND BUNDLED SERVICES |
55 |
| 1.27.6 |
PROVIDER-, PAYER- OR EMPLOYER-SPONSORED ACCESS |
55 |
| 1.27.7 |
ADVERTISING AND LEAD-GENERATION MODEL |
55 |
| 1.27.8 |
DATA ANALYTICS AND INSIGHTS LICENSING |
55 |
| 1.27.9 |
PUBLIC FUNDING AND GOVERNMENT CONTRACT MODEL |
55 |
| 1.28. |
GLOBAL MHEALTH MARKET SHARE BY PRIMARY REVENUE MODEL IN 2024 & 2040 |
56 |
| 1.29. |
MARKET ANALYSIS BY PRIMARY CONNECTIVITY TECHNOLOGY (USD MILLION) |
57 |
| 1.29.1 |
GLOBAL MHEALTH MARKET SHARE BY PRIMARY CONNECTIVITY TECHNOLOGY (2024-2040) |
57 |
| 1.29.2 |
BLUETOOTH AND BLUETOOTH LOW ENERGY |
57 |
| 1.29.3 |
CELLULAR CONNECTIVITY |
57 |
| 1.29.3.1 |
4G/LTE |
57 |
| 1.29.3.2 |
5G |
57 |
| 1.29.3.3 |
LTE-M |
57 |
| 1.29.3.4 |
NB-IoT |
57 |
| 1.29.4 |
WI-FI |
57 |
| 1.29.5 |
NEAR-FIELD COMMUNICATION |
57 |
| 1.29.6 |
LOW-POWER WIDE-AREA NETWORKS |
57 |
| 1.29.7 |
SATELLITE CONNECTIVITY |
57 |
| 1.29.8 |
MULTI-CONNECTIVITY SOLUTIONS |
57 |
| 1.30. |
GLOBAL MHEALTH MARKET SHARE BY PRIMARY CONNECTIVITY TECHNOLOGY IN 2024 & 2040 |
58 |
| 2. |
DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES IN THE MHEALTH MARKET |
59 |
| 2.1. |
DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES ANALYSIS |
59 |
| 2.1.1 |
MARKET DRIVER ANALYSIS |
59 |
| 2.1.1.1 |
Xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxx |
59 |
| 2.1.2 |
MARKET RESTRAINT ANALYSIS |
59 |
| 2.1.2.1 |
Xxxxxxxxxxxxxxxxxxxx Xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx |
59 |
| 2.1.3 |
MARKET OPPORTUNITY |
59 |
| 2.1.3.1 |
Xxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx |
59 |
| 2.1.4 |
MARKET CHALLENGES |
60 |
| 2.1.4.1 |
Xxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxx |
60 |
| 3. |
GLOBAL GROWTH TRENDS |
61 |
| 3.1. |
INDUSTRY TRENDS |
61 |
| 3.1.1 |
SWOT ANALYSIS |
61 |
| 3.1.1.1 |
Strengths |
61 |
| 3.1.1.2 |
Weaknesses |
61 |
| 3.1.1.3 |
Opportunities |
61 |
| 3.1.1.4 |
Threats |
61 |
| 3.1.2 |
PESTEL ANALYSIS |
62 |
| 3.1.2.1 |
Political Landscape |
62 |
| 3.1.2.2 |
Economic Landscape |
62 |
| 3.1.2.3 |
Social Landscape |
63 |
| 3.1.2.4 |
Technological Landscape |
63 |
| 3.1.2.5 |
Environmental Landscape |
63 |
| 3.1.2.6 |
Legal Landscape |
63 |
| 3.1.3 |
PORTER’S FIVE FORCES ANALYSIS |
64 |
| 3.1.3.1 |
Bargaining Power of Suppliers |
64 |
| 3.1.3.2 |
Bargaining Power of Buyers |
65 |
| 3.1.3.3 |
Threat of Substitutesss |
65 |
| 3.1.3.4 |
Threat of New Entrantsss |
65 |
| 3.1.3.5 |
Competitive Rivalry |
65 |
| 3.2. |
POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS |
66 |
| 4. |
POST-COVID-19 ANALYSIS |
67 |
| 4.1. |
V-SHAPED COVID-19 RECOVERY ANALYSIS |
67 |
| 4.2. |
U-SHAPED COVID-19 RECOVERY ANALYSIS |
68 |
| 4.3. |
L-SHAPED COVID-19 RECOVERY ANALYSIS |
68 |
| 4.4. |
W-SHAPED COVID-19 RECOVERY ANALYSIS |
68 |
| 5. |
COMPANIES ANALYSIS |
69 |
| 5.1. |
PLAYERS COVERED: RANKING BY MHEALTH REVENUE |
70 |
| 5.2. |
MARKET SHARE OF LEADING MHEALTH COMPANIES (%) |
70 |
| 6. |
EXECUTIVE SUMMARY |
71 |
| 7. |
GLOBAL MHEALTH MARKET FORECAST, 2020-2040 (USD MILLION) |
73 |
| 7.1. |
GLOBAL MHEALTH REVENUE AND MARKET SHARE BY REGIONS |
73 |
| 7.2. |
GLOBAL MHEALTH MARKET AND MARKET SHARE BY REGION (2020-2025) |
76 |
| 7.3. |
GLOBAL MHEALTH MARKET AND MARKET SHARE BY REGION (2026-2040) |
78 |
| 7.3.1.1 |
North America |
81 |
| 7.3.1.2 |
Europe |
81 |
| 7.3.1.3 |
Asia Pacific |
81 |
| 7.3.1.4 |
Latin America |
81 |
| 7.3.1.5 |
Middle East & Africa |
81 |
| 8. |
NORTH AMERICA MHEALTH MARKET ANALYSIS BY COUNTRY (USD MILLION) |
94 |
| 8.1. |
NORTH AMERICA MHEALTH REVENUE AND MARKET SHARE BY COUNTRY |
94 |
| 8.2. |
NORTH AMERICA MHEALTH MARKET AND MARKET SHARE BY COUNTRY (2020-2025) |
95 |
| 8.3. |
NORTH AMERICA MHEALTH MARKET AND MARKET SHARE BY COUNTRY (2026-2040) |
97 |
| 8.3.1.1 |
United States |
100 |
| 8.3.1.2 |
Canada |
100 |
| 8.3.1.3 |
Mexico |
100 |
| 9. |
EUROPE MHEALTH MARKET ANALYSIS BY COUNTRY (USD MILLION) |
109 |
| 9.1. |
EUROPE MHEALTH REVENUE AND MARKET SHARE BY COUNTRY |
109 |
| 9.2. |
EUROPE MHEALTH MARKET AND MARKET SHARE BY COUNTRY (USD MILLION) (2020-2025) |
110 |
| 9.3. |
EUROPE MHEALTH MARKET AND MARKET SHARE BY COUNTRY (USD MILLION) (2026-2040) |
114 |
| 9.3.1.1 |
United Kingdom |
119 |
| 9.3.1.2 |
Germany |
119 |
| 9.3.1.3 |
France |
119 |
| 9.3.1.4 |
Spain |
119 |
| 9.3.1.5 |
Italy |
119 |
| 9.3.1.6 |
Rest of Europe |
119 |
| 10. |
ASIA PACIFIC MHEALTH MARKET ANALYSIS BY COUNTRY (USD MILLION) (2020-2040) |
134 |
| 10.1. |
ASIA PACIFIC MHEALTH REVENUE AND MARKET SHARE BY COUNTRY |
134 |
| 10.2. |
ASIA PACIFIC MHEALTH MARKET AND MARKET SHARE BY COUNTRY (USD MILLION) (2020-2025) |
135 |
| 10.3. |
ASIA PACIFIC MHEALTH MARKET AND MARKET SHARE BY COUNTRY (USD MILLION) (2026-2040) |
139 |
| 10.3.1.1 |
China |
143 |
| 10.3.1.2 |
India |
143 |
| 10.3.1.3 |
Japan |
143 |
| 10.3.1.4 |
Australia |
143 |
| 10.3.1.5 |
South Korea |
143 |
| 10.3.1.6 |
Rest of Asia Pacific |
143 |
| 11. |
MIDDLE EAST AND AFRICA MHEALTH MARKET ANALYSIS BY COUNTRY (USD MILLION) |
157 |
| 11.1. |
MIDDLE EAST AND AFRICA MHEALTH REVENUE AND MARKET SHARE BY COUNTRY |
157 |
| 11.2. |
MIDDLE EAST & AFRICA MHEALTH MARKET AND MARKET SHARE BY COUNTRY (USD MILLION) (2020-2025) |
158 |
| 11.3. |
MIDDLE EAST & AFRICA MHEALTH MARKET AND MARKET SHARE BY COUNTRY (USD MILLION) (2026-2040) |
160 |
| 11.3.1.1 |
Saudi Arabia |
162 |
| 11.3.1.2 |
South Africa |
162 |
| 11.3.1.3 |
Rest of MEA |
162 |
| 12. |
LATIN AMERICA MHEALTH MARKET ANALYSIS BY COUNTRY (USD MILLION) |
169 |
| 12.1. |
LATIN AMERICA MHEALTH REVENUE AND MARKET SHARE BY COUNTRY |
169 |
| 12.2. |
LATIN AMERICA MHEALTH MARKET AND MARKET SHARE BY COUNTRY (USD MILLION) (2020-2025) |
170 |
| 12.3. |
LATIN AMERICA MHEALTH MARKET AND MARKET SHARE BY COUNTRY (USD MILLION) (2026-2040) |
171 |
| 12.3.1.1 |
Brazil |
174 |
| 12.3.1.2 |
Argentina |
174 |
| 12.3.1.3 |
Rest of Latin America |
174 |
| 13. |
GLOBAL MHEALTH MARKET SEGMENT BY OFFERING (USD MILLION) |
182 |
| 13.1. |
GLOBAL MHEALTH MARKET AND MARKET SHARE BY OFFERING (2020-2025) |
182 |
| 13.2. |
GLOBAL MHEALTH MARKET AND MARKET SHARE BY OFFERING (2026-2040) |
183 |
| 14. |
GLOBAL MHEALTH MARKET SEGMENT BY MHEALTH APPLICATION TYPE (USD MILLION) |
184 |
| 14.1. |
GLOBAL MHEALTH MARKET AND MARKET SHARE BY MHEALTH APPLICATION TYPE (2020-2025) |
184 |
| 14.2. |
GLOBAL MHEALTH MARKET AND MARKET SHARE BY MHEALTH APPLICATION TYPE (2026-2040) |
185 |
| 15. |
GLOBAL MHEALTH MARKET SEGMENT BY CONNECTED DEVICE FORM FACTOR (USD MILLION) |
186 |
| 15.1. |
GLOBAL MHEALTH MARKET AND MARKET SHARE BY CONNECTED DEVICE FORM FACTOR (2020-2025) |
186 |
| 15.2. |
GLOBAL MHEALTH MARKET AND MARKET SHARE BY CONNECTED DEVICE FORM FACTOR (2026-2040) |
187 |
| 16. |
GLOBAL MHEALTH MARKET SEGMENT BY MONITORING AND MEASUREMENT FUNCTION (USD MILLION) |
189 |
| 16.1. |
GLOBAL MHEALTH MARKET AND MARKET SHARE BY MONITORING AND MEASUREMENT FUNCTION (2020-2025) |
189 |
| 16.2. |
GLOBAL MHEALTH MARKET AND MARKET SHARE BY MONITORING AND MEASUREMENT FUNCTION (2026-2040) |
190 |
| 17. |
GLOBAL MHEALTH MARKET SEGMENT BY PRIMARY CLINICAL USE CASE (USD MILLION) |
191 |
| 17.1. |
GLOBAL MHEALTH MARKET AND MARKET SHARE BY PRIMARY CLINICAL USE CASE (2020-2025) |
191 |
| 17.2. |
GLOBAL MHEALTH MARKET AND MARKET SHARE BY PRIMARY CLINICAL USE CASE (2026-2040) |
192 |
| 18. |
GLOBAL MHEALTH MARKET SEGMENT BY DISEASE AND THERAPEUTIC AREA (USD MILLION) |
195 |
| 18.1. |
GLOBAL MHEALTH MARKET AND MARKET SHARE BY DISEASE AND THERAPEUTIC AREA (2020-2025) |
195 |
| 18.2. |
GLOBAL MHEALTH MARKET AND MARKET SHARE BY DISEASE AND THERAPEUTIC AREA (2026-2040) |
196 |
| 19. |
NORTH AMERICA MHEALTH MARKET SEGMENT BY OFFERING (USD MILLION) |
199 |
| 19.1. |
NORTH AMERICA MHEALTH MARKET AND MARKET SHARE BY OFFERING (2020-2025) |
199 |
| 19.2. |
NORTH AMERICA MHEALTH MARKET AND MARKET SHARE BY OFFERING (2026-2040) |
200 |
| 20. |
NORTH AMERICA MHEALTH MARKET SEGMENT BY MHEALTH APPLICATION TYPE (USD MILLION) |
201 |
| 20.1. |
NORTH AMERICA MHEALTH MARKET AND MARKET SHARE BY MHEALTH APPLICATION TYPE (2020-2025) |
201 |
| 20.2. |
NORTH AMERICA MHEALTH MARKET AND MARKET SHARE BY MHEALTH APPLICATION TYPE (2026-2040) |
202 |
| 21. |
NORTH AMERICA MHEALTH MARKET SEGMENT BY CONNECTED DEVICE FORM FACTOR (USD MILLION) |
203 |
| 21.1. |
NORTH AMERICA MHEALTH MARKET AND MARKET SHARE BY CONNECTED DEVICE FORM FACTOR (2020-2025) |
203 |
| 21.2. |
NORTH AMERICA MHEALTH MARKET AND MARKET SHARE BY CONNECTED DEVICE FORM FACTOR (2026-2040) |
204 |
| 22. |
NORTH AMERICA MHEALTH MARKET SEGMENT BY MONITORING AND MEASUREMENT FUNCTION (USD MILLION) |
206 |
| 22.1. |
NORTH AMERICA MHEALTH MARKET AND MARKET SHARE BY MONITORING AND MEASUREMENT FUNCTION (2020-2025) |
206 |
| 22.2. |
NORTH AMERICA MHEALTH MARKET AND MARKET SHARE BY MONITORING AND MEASUREMENT FUNCTION (2026-2040) |
207 |
| 23. |
NORTH AMERICA MHEALTH MARKET SEGMENT BY PRIMARY CLINICAL USE CASE (USD MILLION) |
208 |
| 23.1. |
NORTH AMERICA MHEALTH MARKET AND MARKET SHARE BY PRIMARY CLINICAL USE CASE (2020-2025) |
208 |
| 23.2. |
NORTH AMERICA MHEALTH MARKET AND MARKET SHARE BY PRIMARY CLINICAL USE CASE (2026-2040) |
209 |
| 24. |
NORTH AMERICA MHEALTH MARKET SEGMENT BY DISEASE AND THERAPEUTIC AREA (USD MILLION) |
212 |
| 24.1. |
NORTH AMERICA MHEALTH MARKET AND MARKET SHARE BY DISEASE AND THERAPEUTIC AREA (2020-2025) |
212 |
| 24.2. |
NORTH AMERICA MHEALTH MARKET AND MARKET SHARE BY DISEASE AND THERAPEUTIC AREA (2026-2040) |
213 |
| 25. |
EUROPE MHEALTH MARKET SEGMENT BY OFFERING (USD MILLION) |
216 |
| 25.1. |
EUROPE MHEALTH MARKET AND MARKET SHARE BY OFFERING (2020-2025) |
216 |
| 25.2. |
EUROPE MHEALTH MARKET AND MARKET SHARE BY OFFERING (2026-2040) |
217 |
| 26. |
EUROPE MHEALTH MARKET SEGMENT BY MHEALTH APPLICATION TYPE (USD MILLION) |
218 |
| 26.1. |
EUROPE MHEALTH MARKET AND MARKET SHARE BY MHEALTH APPLICATION TYPE (2020-2025) |
218 |
| 26.2. |
EUROPE MHEALTH MARKET AND MARKET SHARE BY MHEALTH APPLICATION TYPE (2026-2040) |
219 |
| 27. |
EUROPE MHEALTH MARKET SEGMENT BY CONNECTED DEVICE FORM FACTOR (USD MILLION) |
220 |
| 27.1. |
EUROPE MHEALTH MARKET AND MARKET SHARE BY CONNECTED DEVICE FORM FACTOR (2020-2025) |
220 |
| 27.2. |
EUROPE MHEALTH MARKET AND MARKET SHARE BY CONNECTED DEVICE FORM FACTOR (2026-2040) |
221 |
| 28. |
EUROPE MHEALTH MARKET SEGMENT BY MONITORING AND MEASUREMENT FUNCTION (USD MILLION) |
223 |
| 28.1. |
EUROPE MHEALTH MARKET AND MARKET SHARE BY MONITORING AND MEASUREMENT FUNCTION (2020-2025) |
223 |
| 28.2. |
EUROPE MHEALTH MARKET AND MARKET SHARE BY MONITORING AND MEASUREMENT FUNCTION (2026-2040) |
224 |
| 29. |
EUROPE MHEALTH MARKET SEGMENT BY PRIMARY CLINICAL USE CASE (USD MILLION) |
225 |
| 29.1. |
EUROPE MHEALTH MARKET AND MARKET SHARE BY PRIMARY CLINICAL USE CASE (2020-2025) |
225 |
| 29.2. |
EUROPE MHEALTH MARKET AND MARKET SHARE BY PRIMARY CLINICAL USE CASE (2026-2040) |
226 |
| 30. |
EUROPE MHEALTH MARKET SEGMENT BY DISEASE AND THERAPEUTIC AREA (USD MILLION) |
229 |
| 30.1. |
EUROPE MHEALTH MARKET AND MARKET SHARE BY DISEASE AND THERAPEUTIC AREA (2020-2025) |
229 |
| 30.2. |
EUROPE MHEALTH MARKET AND MARKET SHARE BY DISEASE AND THERAPEUTIC AREA (2026-2040) |
230 |
| 31. |
ASIA PACIFIC MHEALTH MARKET SEGMENT BY OFFERING (USD MILLION) |
233 |
| 31.1. |
ASIA PACIFIC MHEALTH MARKET AND MARKET SHARE BY OFFERING (2020-2025) |
233 |
| 31.2. |
ASIA PACIFIC MHEALTH MARKET AND MARKET SHARE BY OFFERING (2026-2040) |
234 |
| 32. |
ASIA PACIFIC MHEALTH MARKET SEGMENT BY MHEALTH APPLICATION TYPE (USD MILLION) |
235 |
| 32.1. |
ASIA PACIFIC MHEALTH MARKET AND MARKET SHARE BY MHEALTH APPLICATION TYPE (2020-2025) |
235 |
| 32.2. |
ASIA PACIFIC MHEALTH MARKET AND MARKET SHARE BY MHEALTH APPLICATION TYPE (2026-2040) |
236 |
| 33. |
ASIA PACIFIC MHEALTH MARKET SEGMENT BY CONNECTED DEVICE FORM FACTOR (USD MILLION) |
237 |
| 33.1. |
ASIA PACIFIC MHEALTH MARKET AND MARKET SHARE BY CONNECTED DEVICE FORM FACTOR (2020-2025) |
237 |
| 33.2. |
ASIA PACIFIC MHEALTH MARKET AND MARKET SHARE BY CONNECTED DEVICE FORM FACTOR (2026-2040) |
238 |
| 34. |
ASIA PACIFIC MHEALTH MARKET SEGMENT BY MONITORING AND MEASUREMENT FUNCTION (USD MILLION) |
240 |
| 34.1. |
ASIA PACIFIC MHEALTH MARKET AND MARKET SHARE BY MONITORING AND MEASUREMENT FUNCTION (2020-2025) |
240 |
| 34.2. |
ASIA PACIFIC MHEALTH MARKET AND MARKET SHARE BY MONITORING AND MEASUREMENT FUNCTION (2026-2040) |
241 |
| 35. |
ASIA PACIFIC MHEALTH MARKET SEGMENT BY PRIMARY CLINICAL USE CASE (USD MILLION) |
242 |
| 35.1. |
ASIA PACIFIC MHEALTH MARKET AND MARKET SHARE BY PRIMARY CLINICAL USE CASE (2020-2025) |
242 |
| 35.2. |
ASIA PACIFIC MHEALTH MARKET AND MARKET SHARE BY PRIMARY CLINICAL USE CASE (2026-2040) |
243 |
| 36. |
ASIA PACIFIC MHEALTH MARKET SEGMENT BY DISEASE AND THERAPEUTIC AREA (USD MILLION) |
246 |
| 36.1. |
ASIA PACIFIC MHEALTH MARKET AND MARKET SHARE BY DISEASE AND THERAPEUTIC AREA (2020-2025) |
246 |
| 36.2. |
ASIA PACIFIC MHEALTH MARKET AND MARKET SHARE BY DISEASE AND THERAPEUTIC AREA (2026-2040) |
247 |
| 37. |
LATIN AMERICA MHEALTH MARKET SEGMENT BY OFFERING (USD MILLION) |
250 |
| 37.1. |
LATIN AMERICA MHEALTH MARKET AND MARKET SHARE BY OFFERING (2020-2025) |
250 |
| 37.2. |
LATIN AMERICA MHEALTH MARKET AND MARKET SHARE BY OFFERING (2026-2040) |
251 |
| 38. |
LATIN AMERICA MHEALTH MARKET SEGMENT BY MHEALTH APPLICATION TYPE (USD MILLION) |
252 |
| 38.1. |
LATIN AMERICA MHEALTH MARKET AND MARKET SHARE BY MHEALTH APPLICATION TYPE (2020-2025) |
252 |
| 38.2. |
LATIN AMERICA MHEALTH MARKET AND MARKET SHARE BY MHEALTH APPLICATION TYPE (2026-2040) |
253 |
| 39. |
LATIN AMERICA MHEALTH MARKET SEGMENT BY CONNECTED DEVICE FORM FACTOR (USD MILLION) |
254 |
| 39.1. |
LATIN AMERICA MHEALTH MARKET AND MARKET SHARE BY CONNECTED DEVICE FORM FACTOR (2020-2025) |
254 |
| 39.2. |
LATIN AMERICA MHEALTH MARKET AND MARKET SHARE BY CONNECTED DEVICE FORM FACTOR (2026-2040) |
255 |
| 40. |
LATIN AMERICA MHEALTH MARKET SEGMENT BY MONITORING AND MEASUREMENT FUNCTION (USD MILLION) |
257 |
| 40.1. |
LATIN AMERICA MHEALTH MARKET AND MARKET SHARE BY MONITORING AND MEASUREMENT FUNCTION (2020-2025) |
257 |
| 40.2. |
LATIN AMERICA MHEALTH MARKET AND MARKET SHARE BY MONITORING AND MEASUREMENT FUNCTION (2026-2040) |
258 |
| 41. |
LATIN AMERICA MHEALTH MARKET SEGMENT BY PRIMARY CLINICAL USE CASE (USD MILLION) |
259 |
| 41.1. |
LATIN AMERICA MHEALTH MARKET AND MARKET SHARE BY PRIMARY CLINICAL USE CASE (2020-2025) |
259 |
| 41.2. |
LATIN AMERICA MHEALTH MARKET AND MARKET SHARE BY PRIMARY CLINICAL USE CASE (2026-2040) |
260 |
| 42. |
LATIN AMERICA MHEALTH MARKET SEGMENT BY DISEASE AND THERAPEUTIC AREA (USD MILLION) |
263 |
| 42.1. |
LATIN AMERICA MHEALTH MARKET AND MARKET SHARE BY DISEASE AND THERAPEUTIC AREA (2020-2025) |
263 |
| 42.2. |
LATIN AMERICA MHEALTH MARKET AND MARKET SHARE BY DISEASE AND THERAPEUTIC AREA (2026-2040) |
264 |
| 43. |
MIDDLE EAST & AFRICA MHEALTH MARKET SEGMENT BY OFFERING (USD MILLION) |
267 |
| 43.1. |
MIDDLE EAST & AFRICA MHEALTH MARKET AND MARKET SHARE BY OFFERING (2020-2025) |
267 |
| 43.2. |
MIDDLE EAST & AFRICA MHEALTH MARKET AND MARKET SHARE BY OFFERING (2026-2040) |
268 |
| 44. |
MIDDLE EAST & AFRICA MHEALTH MARKET SEGMENT BY MHEALTH APPLICATION TYPE (USD MILLION) |
269 |
| 44.1. |
MIDDLE EAST & AFRICA MHEALTH MARKET AND MARKET SHARE BY MHEALTH APPLICATION TYPE (2020-2025) |
269 |
| 44.2. |
MIDDLE EAST & AFRICA MHEALTH MARKET AND MARKET SHARE BY MHEALTH APPLICATION TYPE (2026-2040) |
270 |
| 45. |
MIDDLE EAST & AFRICA MHEALTH MARKET SEGMENT BY CONNECTED DEVICE FORM FACTOR (USD MILLION) |
271 |
| 45.1. |
MIDDLE EAST & AFRICA MHEALTH MARKET AND MARKET SHARE BY CONNECTED DEVICE FORM FACTOR (2020-2025) |
271 |
| 45.2. |
MIDDLE EAST & AFRICA MHEALTH MARKET AND MARKET SHARE BY CONNECTED DEVICE FORM FACTOR (2026-2040) |
272 |
| 46. |
MIDDLE EAST & AFRICA MHEALTH MARKET SEGMENT BY MONITORING AND MEASUREMENT FUNCTION (USD MILLION) |
274 |
| 46.1. |
MIDDLE EAST & AFRICA MHEALTH MARKET AND MARKET SHARE BY MONITORING AND MEASUREMENT FUNCTION (2020-2025) |
274 |
| 46.2. |
MIDDLE EAST & AFRICA MHEALTH MARKET AND MARKET SHARE BY MONITORING AND MEASUREMENT FUNCTION (2026-2040) |
275 |
| 47. |
MIDDLE EAST & AFRICA MHEALTH MARKET SEGMENT BY PRIMARY CLINICAL USE CASE (USD MILLION) |
276 |
| 47.1. |
MIDDLE EAST & AFRICA MHEALTH MARKET AND MARKET SHARE BY PRIMARY CLINICAL USE CASE (2020-2025) |
276 |
| 47.2. |
MIDDLE EAST & AFRICA MHEALTH MARKET AND MARKET SHARE BY PRIMARY CLINICAL USE CASE (2026-2040) |
277 |
| 48. |
MIDDLE EAST & AFRICA MHEALTH MARKET SEGMENT BY DISEASE AND THERAPEUTIC AREA (USD MILLION) |
280 |
| 48.1. |
MIDDLE EAST & AFRICA MHEALTH MARKET AND MARKET SHARE BY DISEASE AND THERAPEUTIC AREA (2020-2025) |
280 |
| 48.2. |
MIDDLE EAST & AFRICA MHEALTH MARKET AND MARKET SHARE BY DISEASE AND THERAPEUTIC AREA (2026-2040) |
281 |
| 49. |
COMPANY PROFILES (CONNECTED DEVICES, WEARABLES AND MEDICAL MONITORING COMPANIES) |
284 |
| 49.1. |
APPLE INC |
284 |
| 49.1.1 |
COMPANY DETAILS |
284 |
| 49.1.2 |
FINANCIALS (USD MILLIONS) |
284 |
| 49.1.3 |
PRODUCT SUMMARY |
284 |
| 49.1.4 |
RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS) |
285 |
| 49.2. |
ALPHABET INC. (GOOGLE/FITBIT) |
286 |
| 49.3. |
SAMSUNG ELECTRONICS CO., LTD |
286 |
| 49.4. |
HUAWEI TECHNOLOGIES CO., LTD |
286 |
| 49.5. |
XIAOMI CORPORATION |
286 |
| 49.6. |
GARMIN LTD |
286 |
| 49.7. |
OURA HEALTH OY |
286 |
| 49.8. |
WHOOP, INC |
286 |
| 49.9. |
WITHINGS |
286 |
| 49.10. |
ZEPP HEALTH CORPORATION |
286 |
| 49.11. |
POLAR ELECTRO OY |
286 |
| 49.12. |
ABBOTT LABORATORIES |
286 |
| 49.13. |
DEXCOM, INC |
286 |
| 49.14. |
MEDTRONIC PLC |
286 |
| 49.15. |
INSULET CORPORATION |
286 |
| 49.16. |
TANDEM DIABETES CARE, INC |
286 |
| 49.17. |
SENSEONICS HOLDINGS, INC |
286 |
| 49.18. |
F. HOFFMANN-LA ROCHE LTD |
286 |
| 49.19. |
YPSOMED HOLDING AG |
286 |
| 49.20. |
KONINKLIJKE PHILIPS N.V |
286 |
| 49.21. |
GE HEALTHCARE TECHNOLOGIES INC |
286 |
| 49.22. |
SIEMENS HEALTHINEERS AG |
286 |
| 49.23. |
BOSTON SCIENTIFIC CORPORATION |
286 |
| 49.24. |
MASIMO CORPORATION |
286 |
| 49.25. |
OMRON HEALTHCARE CO., LTD |
286 |
| 49.26. |
IRHYTHM TECHNOLOGIES, INC |
286 |
| 49.27. |
RESMED INC |
286 |
| 49.28. |
ZOLL MEDICAL CORPORATION |
286 |
| 49.29. |
BIOINTELLISENSE, INC |
286 |
| 49.30. |
VITALCONNECT, INC |
286 |
| 49.31. |
EMPATICA INC |
286 |
| 49.32. |
SIBEL HEALTH, INC |
286 |
| 49.33. |
ALIVECOR, INC |
286 |
| 49.34. |
EKO HEALTH, INC |
287 |
| 49.35. |
BUTTERFLY NETWORK, INC |
287 |
| 49.36. |
CLARIUS MOBILE HEALTH CORP |
287 |
| 49.37. |
TYTOCARE LTD |
287 |
| 49.38. |
HEALTHY.IO LTD |
287 |
| 49.39. |
BINAH.AI LTD |
287 |
| 49.40. |
QOMPIUM NV |
287 |
| 49.41. |
AKTIIA SA |
287 |
| 49.42. |
BIOBEAT TECHNOLOGIES LTD |
287 |
| 49.43. |
CARDIACSENSE LTD |
287 |
| 49.44. |
CORSANO HEALTH B.V |
287 |
| 49.45. |
SMARTCARDIA SA |
287 |
| 49.46. |
LIFESIGNALS, INC |
287 |
| 49.47. |
VIVALINK, INC |
287 |
| 49.48. |
BIOFOURMIS, INC |
287 |
| 49.49. |
HUMA THERAPEUTICS LIMITED |
287 |
| 49.50. |
CURRENT HEALTH |
287 |
| 49.51. |
OTHERS |
287 |
| 50. |
COMPANY PROFILES (TELEHEALTH AND MOBILE VIRTUAL-CARE COMPANIES) |
288 |
| 50.1. |
TELADOC HEALTH, INC |
288 |
| 50.1.1 |
COMPANY DETAILS |
288 |
| 50.1.2 |
FINANCIALS (USD MILLIONS) |
288 |
| 50.1.3 |
PRODUCT SUMMARY |
288 |
| 50.1.4 |
RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS) |
289 |
| 50.2. |
AMERICAN WELL CORPORATION |
289 |
| 50.3. |
INCLUDED HEALTH, INC |
289 |
| 50.4. |
DOXIMITY, INC |
289 |
| 50.5. |
AMAZON ONE MEDICAL |
289 |
| 50.6. |
HIMS & HERS HEALTH, INC |
289 |
| 50.7. |
K HEALTH, INC |
289 |
| 50.8. |
HEALTHTAP, INC |
289 |
| 50.9. |
EVISIT, INC |
289 |
| 50.10. |
MDLIVE INC |
289 |
| 50.11. |
DOCTOLIB SAS |
289 |
| 50.12. |
KRY INTERNATIONAL AB (LIVI) |
289 |
| 50.13. |
DOCPLANNER GROUP |
289 |
| 50.14. |
PRACTO TECHNOLOGIES PVT. LTD |
289 |
| 50.15. |
HALODOC |
289 |
| 50.16. |
DOCTOR ANYWHERE PTE. LTD |
289 |
| 50.17. |
PING AN HEALTHCARE AND TECHNOLOGY COMPANY LIMITED |
289 |
| 50.18. |
JD HEALTH INTERNATIONAL INC |
289 |
| 50.19. |
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED |
289 |
| 50.20. |
MAVEN CLINIC CO |
289 |
| 50.21. |
OTHERS |
289 |
| 51. |
COMPANY PROFILES (CHRONIC DISEASE MANAGEMENT AND DIGITAL THERAPEUTICS COMPANIES) |
290 |
| 51.1. |
OMADA HEALTH, INC |
290 |
| 51.1.1 |
COMPANY DETAILS |
290 |
| 51.1.2 |
FINANCIALS (USD MILLIONS) |
290 |
| 51.1.3 |
PRODUCT SUMMARY |
290 |
| 51.1.4 |
RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS) |
291 |
| 51.2. |
VIRTA HEALTH CORP |
291 |
| 51.3. |
DARIOHEALTH CORP |
291 |
| 51.4. |
WELLDOC, INC |
291 |
| 51.5. |
LARK TECHNOLOGIES, INC |
291 |
| 51.6. |
NOOM, INC |
291 |
| 51.7. |
HINGE HEALTH, INC |
291 |
| 51.8. |
SWORD HEALTH TECHNOLOGIES, INC |
291 |
| 51.9. |
KAIA HEALTH SOFTWARE GMBH |
291 |
| 51.10. |
SIDEKICK HEALTH |
291 |
| 51.11. |
HELLOBETTER |
291 |
| 51.12. |
BIG HEALTH LTD |
291 |
| 51.13. |
CLICK THERAPEUTICS, INC |
291 |
| 51.14. |
VIRTUAL THERAPEUTICS |
291 |
| 51.15. |
WELT CORP |
291 |
| 51.16. |
OTHERS |
291 |
| 52. |
COMPANY PROFILES (MENTAL AND BEHAVIORAL MHEALTH COMPANIES) |
292 |
| 52.1. |
HEADSPACE HEALTH |
292 |
| 52.1.1 |
COMPANY DETAILS |
292 |
| 52.1.2 |
FINANCIALS (USD MILLIONS) |
292 |
| 52.1.3 |
PRODUCT SUMMARY |
292 |
| 52.1.4 |
RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS) |
293 |
| 52.2. |
CALM.COM, INC |
293 |
| 52.3. |
TALKSPACE, INC |
293 |
| 52.4. |
SPRING HEALTH |
293 |
| 52.5. |
WYSA LTD |
293 |
| 52.6. |
OTHERS |
293 |
| 53. |
COMPANY PROFILES (REMOTE PATIENT MONITORING AND CARE-MANAGEMENT COMPANIES) |
294 |
| 53.1. |
CADENCE SOLUTIONS |
294 |
| 53.1.1 |
COMPANY DETAILS |
294 |
| 53.1.2 |
FINANCIALS (USD MILLIONS) |
294 |
| 53.1.3 |
PRODUCT SUMMARY |
294 |
| 53.1.4 |
RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS) |
295 |
| 53.2. |
HEALTH RECOVERY SOLUTIONS, INC |
295 |
| 53.3. |
COACHCARE |
295 |
| 53.4. |
VALIDIC, INC |
295 |
| 53.5. |
DATOS HEALTH |
295 |
| 53.6. |
RIMIDI, INC |
295 |
| 53.7. |
LUSCII HEALTHTECH B.V |
295 |
| 53.8. |
DOCCLA LTD |
295 |
| 53.9. |
CARESIMPLE, INC |
295 |
| 53.10. |
VETA HEALTH LLC |
295 |
| 53.11. |
OTHERS |
295 |
| 54. |
CONCLUSION |
296 |
| 55. |
REFERENCE LINK |
297 |
| 56. |
APPENDIX |
298 |
| 56.1. |
METHODOLOGY |
298 |
| 56.2. |
RESEARCH DATA SOURCE |
299 |
| 56.2.1 |
SECONDARY DATA |
299 |
| 56.2.2 |
KEY DATA FROM SECONDARY |
300 |
| 56.2.3 |
PRIMARY DATA |
301 |
| 56.2.4 |
KEY DATA FROM PRIMARY |
301 |
| 56.2.5 |
INDUSTRY INSIGHTS FROM PROFESSIONAL LEADERS |
302 |
| 56.2.6 |
MARKET ESTIMATION |
302 |
| 56.2.7 |
MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACHES |
304 |
| 56.2.8 |
LEGAL DISCLAIMER |
304 |
| 57. |
RESEARCH SCOPE |
305 |